Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

January 10, 2019 by Alan Khadavi

New Eczema Medications in the Pipeline

In the past year or so, new eczema medications have been released that have been highly beneficial for patients.  We have seen Eucrisa (crisaborole) New Eczema Medication gets FDA Approval, this is a topical medication which is an inhibitor of phosphodiesterase 4-depndent cyclic adenosine monophosphate degradation.  It was approved in 2016 for mild to moderate atopic dermatitis in patients over 2 years of age.  It has a low frequency of side effects and it is steroid sparing.

Dupilumab (Dupixent) for Atopic Dermatitis (Eczema) Sufferers is used to treat moderate to severe eczema and it has been shown to be highly efficacious in moderate to severe atopic dermatitis.

New eczema medications that may be emerging are:

  • Tralokinumab, we have discussed previously for asthma. Tralokinumab for Asthma It is an anti-IL-13 agent.  It has shown to improve eczema scores given as an injection every 2 weeks and it improved skin clearance.  Patients also reported improved quality of life and itching.
  • Nemolizumab is an anti-IL-31 receptor A agent. Nemolizumab for Itching and Atopic Dermatitis This has shown promising results in reducing itching in patients with eczema.  Itching has implications for sleep disturbance and poor quality of life.  In a recent trial, all patients who received nemolizumab had significant reduction in itching.  Nemolizumab has shown promising results and remains in the pipeline as a potential future biological therapy.
  • Ustekinumab is another agent that targets IL-12/IL-23p40 to suppress TH1, TH17, and TH 22 activation.  It has clinical approval for use in patients with psoriasis and has demonstrated clinical efficacy and safety for that condition, but its efficacy and safety for atopic dermatitis are not as well known.  Stelara for Plaque Psoriasis  Patients with moderate to severe eczema underwent treatment and the results were not very different than those who received placebo.  More investigation will be needed for ustekinumab to see if this will have any clinical benefit in the future.

Atopic dermatitis is a very common skin disease and it can affect up to 20% of the population, the majority of patients are children.  Great advances have already been made and with more research, we are learning more about the molecular environment of the affected skin.  Filaggrin and Thymic Stromal Lymphopoietin are also being studied for potential new eczema medications in the future.

Filed Under: atopic dermatitis, biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page